Brick Top
New member
- Joined
- Feb 18, 2022
- Messages
- 67
- Reaction score
- 217
Good to see some leasing activity in this one:
www.bizjournals.com/boston/news/2023/08/10/cambridge-crossing-lands-lab-leases.html
Commercial Real Estate
Astellas signs lease at new Cambridge Crossing lab building
From the article:
(emphasis mine)The Japanese pharmaceutical giant will occupy about 62,000 square feet at 441 Morgan Ave., a 10-story building whose core and shell is nearly fully built out. It expects to move into the facility next year.
Astellas has about 25,000 square feet at 1030 Massachusetts Ave. near Cambridge’s Central Square that it will vacate. Its Cambridge Crossing space will include labs and offices, including an incubator space for partner businesses. The location is expected to ultimately house a few hundred employees in areas like research and business development. The move will not affect operations at the Astellas Institute of Regenerative Medicine in Westborough.
That the Astellas lease is one of 2023’s largest speaks to how much demand for life sciences space has fallen over the past year. In 2022, there were at least seven lab leases of more than 200,000 square feet, including Takeda and AstraZeneca mega-leases in Kendall Square.
So a net change of +37,000 square feet is one of the largest leases of 2023. I'd love to be a fly on the wall in the boardroom of a developer with lab space currently under construction. I bet they are sweating bullets, desperately hoping that they're not throwing away hundreds of millions of dollars to construct buildings that will sit empty.